close

Company to cut drug price after gouging accusations

2 min read

Notice: Undefined variable: article_ad_placement3 in /usr/web/cs-washington.ogdennews.com/wp-content/themes/News_Core_2023_WashCluster/single.php on line 128

SAN FRANCISCO – The company that sparked an angry backlash after it raised the price of a drug for treating a deadly parasitic infection by more than 5,000 percent said it will roll back some of the increase.

Turing Pharmaceuticals CEO Martin Shkreli told ABC News Tuesday the new price would make Daraprim more accessible, although he did not say what the new price for the drug would be. A spokesman for Turing did not immediately respond to a request for details.

“We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit,” Shkreli told ABC.

The company obtained rights to sell the drug, the only U.S.-approved treatment for toxoplasmosis, in August. It hiked the price overnight from $13.50 per pill to $750.

Turing said it would use profits to improve the drug’s formulation and develop new, better drugs for the infection. It also stressed some patients can get financial aid from the company to obtain the drug.

But the price increase sparked outrage from medical groups representing doctors who care for patients with HIV and other infectious diseases, because Daraprim treats patients with compromised immune systems.

Hillary Rodham Clinton called Turing’s price hike “outrageous” in a tweet Monday. While campaigning for the Democratic nomination for president Tuesday, she outlined a broad plan aimed at holding down the cost of prescription drugs.

CUSTOMER LOGIN

If you have an account and are registered for online access, sign in with your email address and password below.

NEW CUSTOMERS/UNREGISTERED ACCOUNTS

Never been a subscriber and want to subscribe, click the Subscribe button below.

Starting at $3.75/week.

Subscribe Today